PCVX stock forecast, quote, news & analysis
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases... Show more
Why Vaxcyte (PCVX) Stock Is Up +15% in the Last 30 Days
Key Takeaways
- Vaxcyte shares rose roughly 15% over the 30-day period through October 20, 2026, climbing from a closing price of $58.13 on September 18 to about $66.83.
- The advance was driven by positive topline results from the OPUS-1 pivotal adult Phase 3 trial of VAX-31, Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, announced on October 5.
- Shares spiked as high as $90.75 intraday before retreating, as the company disclosed a $1.15 billion equity and convertible debt financing shortly after the data readout.
- Sell-side reaction was favorable: Mizuho maintained a Buy rating with a $163 price target, while Needham raised its target to $122 from $110.
- Vaxcyte expects to report OPUS-2 and OPUS-3 adult Phase 3 data in the first half of 2027 and plans a Biologics License Application submission in the first half of 2028.
Vaxcyte (PCVX) Company Overview and Market Position
Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California, focused on engineering high-fidelity vaccines against bacterial diseases. Its lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) described by the company as the broadest-spectrum PCV in the clinic today, targeting prevention of invasive pneumococcal disease (IPD). The pipeline also includes VAX-24, a 24-valent PCV candidate, and VAX-A1, a prophylactic candidate for Group A Strep currently in Phase 1 testing.
The company's vaccine candidates are built on its XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma (STRO). Investors follow PCVX closely because the pneumococcal vaccine market is a multibillion-dollar category dominated by established players such as Pfizer (PFE) and Merck (MRK), and broader serotype coverage could position Vaxcyte's candidates as differentiated, potentially best-in-class options.
Vaxcyte (PCVX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PCVX advanced approximately 15%, rising from a close of $58.13 on September 18 to roughly $66.83 by October 20, 2026. The gain was concentrated around a single catalyst: on October 5, the stock opened at $87.21, well above its prior close of $56.48, and touched an intraday high of $90.75 before profit-taking and a subsequent capital raise pulled shares back into the mid-$60s.
Over the last quarter, the move is more pronounced. From the mid-$55 range in mid-July, the stock has risen roughly 20%, though the path was uneven. For much of the period the shares traded in a range between roughly $52 and $63 as investors awaited pivotal data, before the October readout re-rated the stock higher. The net result is a sharp upward step, followed by a consolidation phase.
What Drove PCVX Stock Price in the Last 30 Days
The primary driver was the October 5 announcement of positive topline results from the OPUS-1 adult Phase 3 trial of VAX-31. The candidate met all prespecified primary endpoints across the age groups studied against Prevnar 20 and Capvaxive. In adults aged 50 and older, VAX-31 met the non-inferiority threshold for all 28 serotypes shared with the comparator vaccines, while the three serotypes unique to VAX-31 and cross-reactive serotype 20B met superiority criteria. The trial enrolled 4,047 participants across roughly 30 U.S. sites, and the vaccine was well tolerated with a safety profile similar to PCV20 and PCV21.
The data drew a sharp positive response from analysts. Mizuho called the results "very clean" and "near best-case scenario," reiterating a Buy rating and a $163 price target. Needham raised its price target to $122 from $110. The enthusiasm was tempered by a subsequent financing: on October 9, Vaxcyte closed a $1.15 billion offering of common stock at $64.00 per share, pre-funded warrants, and 1.50% convertible senior notes due 2032, adding supply that contributed to the stock's pullback from its post-data highs.
What Drove PCVX Stock Performance Over the Last Quarter
The broader quarterly trend was defined by anticipation of the VAX-31 pivotal readout. For most of the summer and early fall, shares traded in a relatively narrow range as investors weighed the potential for Vaxcyte to disrupt the established pneumococcal vaccine market held by Pfizer and Merck. The October OPUS-1 results validated the clinical thesis, shifting the narrative from a speculative pre-data story to a company with a credible late-stage, potentially best-in-class asset and a clearer path toward commercialization.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-driven trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section, helping traders filter for strategies with demonstrated momentum. These bots vary in trading strategy, timeframe, and performance metrics, so investors can explore different approaches aligned with their own objectives. For those interested in automated, data-driven market analysis, the page offers a practical starting point for discovering high-performing AI trading tools.
PCVX Stock Forecast Drivers: What Investors Should Watch Next
The next major catalysts are the OPUS-2 and OPUS-3 adult Phase 3 readouts, which Vaxcyte expects to report in the first half of 2027, along with topline data from the VAX-31 infant Phase 2 dose-finding study. A planned Biologics License Application submission in the first half of 2028 represents the key regulatory milestone on the path to a potential U.S. launch. Investors will also monitor manufacturing scale-up, competitive dynamics with Pfizer and Merck, and how the $1.15 billion financing supports the company's clinical and pre-commercial investments. Macroeconomic and sector-level biotech sentiment may continue to influence valuation alongside these company-specific events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PCVX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PCVX turned positive on November 09, 2026. Looking at past instances where PCVX's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PCVX as a result. In 63 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
PCVX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PCVX crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.
Following a +9.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where PCVX advanced for three days, in 222 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for PCVX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 25 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PCVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
PCVX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.447) is normal, around the industry mean (3.498). P/E Ratio (-8.374) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PCVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PCVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of vaccines for infectious diseases
Industry Biotechnology